Evaluation of biological drug consumption in Italy during 2022: a comparative analysis between two healthcare facilities.

IF 1.8 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-02-20 DOI:10.1080/14737167.2025.2465445

Marcello Vaccaro, Giacomo Polito, Gabriele Bagaglini, Maurizio Capuozzo, Roberto Langella, Eduardo Nava, Andrea Zovi, Francesco Ferrara

{"title":"Evaluation of biological drug consumption in Italy during 2022: a comparative analysis between two healthcare facilities.","authors":"Marcello Vaccaro, Giacomo Polito, Gabriele Bagaglini, Maurizio Capuozzo, Roberto Langella, Eduardo Nava, Andrea Zovi, Francesco Ferrara","doi":"10.1080/14737167.2025.2465445","DOIUrl":null,"url":null,"abstract":"Background: Biosimilar drugs represent a valuable opportunity for healthcare systems worldwide as they offer substantial cost savings. This retrospective observational study aimed to assess the current prescribing trend in order to raise awareness among physicians for more appropriate prescribing.Research design and methods: A study was conducted to assess the use of major biologic drugs across different therapeutic areas within two Italian healthcare entities. Usage and cost data were obtained from company databases. In addition, a comparison with 2021 data was performed to identify any increases in biosimilar drug utilization during 2022.Results: The analysis for 2022 revealed that the majority of studied active ingredients have been administered as biosimilar drugs, with percentages close to 100%, except for a few exceptions. In particular, resistance remained in the prescription of biosimilar adalimumab (73.8%) and etanercept (73.3%) in Asl Napoli 3 Sud, erythropoietin (69.5%) and rituximab (72.8%) in Policlinico Umberto I.Conclusions: A comparison between 2021 and 2022 highlighted the increasing adoption of biosimilar drugs. This positive trend suggested the potential for full utilization in the near future, benefiting significantly the National Health System and the public, ensuring a healthcare approach that is effective and sustainable.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-7"},"PeriodicalIF":1.8000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2025.2465445","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Biosimilar drugs represent a valuable opportunity for healthcare systems worldwide as they offer substantial cost savings. This retrospective observational study aimed to assess the current prescribing trend in order to raise awareness among physicians for more appropriate prescribing.

Research design and methods: A study was conducted to assess the use of major biologic drugs across different therapeutic areas within two Italian healthcare entities. Usage and cost data were obtained from company databases. In addition, a comparison with 2021 data was performed to identify any increases in biosimilar drug utilization during 2022.

Results: The analysis for 2022 revealed that the majority of studied active ingredients have been administered as biosimilar drugs, with percentages close to 100%, except for a few exceptions. In particular, resistance remained in the prescription of biosimilar adalimumab (73.8%) and etanercept (73.3%) in Asl Napoli 3 Sud, erythropoietin (69.5%) and rituximab (72.8%) in Policlinico Umberto I.

Conclusions: A comparison between 2021 and 2022 highlighted the increasing adoption of biosimilar drugs. This positive trend suggested the potential for full utilization in the near future, benefiting significantly the National Health System and the public, ensuring a healthcare approach that is effective and sustainable.

查看原文本刊更多论文

2022 年意大利生物药品消耗量评估：两家医疗机构的对比分析。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.